← Leaderboards
Brian Crompton
University Of California, San Francisco
$6,355,467
Attributed
$6,912,460
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,912,460 · 5
By mechanism
R37$2,810,448 · 1
P50$2,102,426 · 2
R01$1,113,986 · 1
K08$885,600 · 1
Top collaborators
- Kieuhoa Tran Vo2 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Eric Alejandro Sweet-Cordero$20,798,239
- William A Weiss$31,543,847
- Miller Huang$1,680,627
- Michael D. Taylor$7,522,868
- Amit J. Sabnis$2,108,153
Others in their field
Top investigators on “Recurrence”
- Philip J Disaia · University Of California Irvine$95,481,777
- David Heimbrook · Leidos Biomedical Research, Inc.$87,033,539
- Wafaa M. El-Sadr · Columbia University Health Sciences$84,793,830
- Myron S Cohen · Family Health International$84,793,830
- Lawrence Corey · Fred Hutchinson Cancer Center$59,594,035
- Dan H. Barouch · Fred Hutchinson Cancer Center$59,594,035
Research focus
RecurrenceDeep SequencingTumorMalignant NeoplasmsCollectionFutureNext Generation SequencingTherapy ResistantResponseTechnologyDetectionSamplingPlasmaPatternRelapseBloodBiopsy SpecimenEvolutionBlood SpecimenOperative Surgical ProceduresLiquid BiopsyPreventResistanceTumor Dna
Grant awards (17)
Liquid biopsy approaches to inform osteosarcoma prognosis and tumor evolution$814,350
R37 · FY2025 · CA · contact PI
Circulating biomarkers of clinical response to combination targeted therapies in neuroblastoma$540,607
R01 · FY2025 · CA
PROJECT 3: Applying Liquid Biopsy Technologies to Detect Clinical Response and Mechanisms of Resistance in the Treatment of LMS$528,278
P50 · FY2025 · CA · contact PI
Circulating biomarkers of clinical response to combination targeted therapies in neuroblastoma$573,379
R01 · FY2024 · CA
PROJECT 3: Applying Liquid Biopsy Technologies to Detect Clinical Response and Mechanisms of Resistance in the Treatment of LMS$520,446
P50 · FY2024 · CA · contact PI
Liquid biopsy approaches to inform osteosarcoma prognosis and tumor evolution$384,644
R37 · FY2024 · CA · contact PI
PROJECT 3: Applying Liquid Biopsy Technologies to Detect Clinical Response and Mechanisms of Resistance in the Treatment of LMS$541,504
P50 · FY2023 · CA · contact PI
Liquid biopsy approaches to inform osteosarcoma prognosis and tumor evolution$396,790
R37 · FY2023 · CA · contact PI
PROJECT 3: Applying Liquid Biopsy Technologies to Detect Clinical Response and Mechanisms of Resistance in the Treatment of LMS$512,198
P50 · FY2022 · CA · contact PI
Liquid biopsy approaches to inform osteosarcoma prognosis and tumor evolution$404,888
R37 · FY2022 · CA · contact PI
Liquid biopsy approaches to inform osteosarcoma prognosis and tumor evolution$404,888
R37 · FY2021 · CA · contact PI
Liquid biopsy approaches to inform osteosarcoma prognosis and tumor evolution$404,888
R37 · FY2020 · CA · contact PI
Targeting FAK and integrin signaling in preclinical models of Ewing sarcoma$177,120
K08 · FY2019 · CA · contact PI
Targeting FAK and integrin signaling in preclinical models of Ewing sarcoma$177,120
K08 · FY2018 · CA · contact PI
Targeting FAK and integrin signaling in preclinical models of Ewing sarcoma$177,120
K08 · FY2017 · CA · contact PI
Targeting FAK and integrin signaling in preclinical models of Ewing sarcoma$177,120
K08 · FY2016 · CA · contact PI
Targeting FAK and integrin signaling in preclinical models of Ewing sarcoma$177,120
K08 · FY2015 · CA · contact PI